

## Table of Contents

INTRODUCTION .....	4
Methodology .....	4
ORAL PHARMACEUTICALS TO TREAT INTERMITTENT CLAUDICATION .....	5
Stand-Alone Therapies for Claudication Symptoms .....	5
Therapies to be Employed with Exercise Training .....	7
INTERMITTENT CLAUDICATION—FAILED PHARMACEUTICAL THERAPIES .	7
ORAL MEDICATIONS TO PREVENT ISCHEMIC EVENTS .....	10
Anticoagulants—Thrombin Inhibitors in Clinical Trials.....	10
Anticoagulants—Factor Xa Inhibitors in Clinical Trials.....	11
Anticoagulants—New Heparin Formulations in Clinical Trials .....	13
Antiplatelets in Clinical Trials .....	14
Antiplatelets—Oral GP IIb/IIIa Inhibitors Discontinued Due to Safety Concerns .....	15
ANGIOGENESIS THERAPIES FOR INTERMITTENT CLAUDICATION AND CRITICAL LIMB ISCHEMIA.....	16
Angiogenesis Trials for Peripheral Arterial Disease—Mixed Results .....	16
Gene and Protein Therapies in Human Clinical Trials .....	18
CELL THERAPIES FOR INTERMITTENT CLAUDICATION AND CRITICAL LIMB ISCHEMIA .....	20
United States Clinical Trials—Company Sponsored.....	20
United States Clinical Trials—University Sponsored .....	21
International Clinical Trials .....	21
Israel and South America.....	23
Far East .....	24
REFERENCES .....	25
INDEX OF TABLES .....	27
LIST OF ACRONYMS .....	28
DISCLOSURE STATEMENT .....	29
Stock Ownership .....	29
CONTACT INFORMATION.....	30